Free Trial

Oncology Institute (TOI) Competitors

Oncology Institute logo
$5.31 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$5.32 +0.01 (+0.19%)
As of 06/12/2026 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TOI vs. SGRY, ADUS, AGL, SNDA, and VRDN

Should you buy Oncology Institute stock or one of its competitors? MarketBeat compares Oncology Institute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncology Institute include Surgery Partners (SGRY), Addus HomeCare (ADUS), Agilon Health (AGL), Sonida Senior Living (SNDA), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry.

How does Oncology Institute compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Oncology Institute (NASDAQ:TOI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Oncology Institute has lower revenue, but higher earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgery Partners$3.31B0.61-$77.90M-$0.60N/A
Oncology Institute$545.76M0.96-$60.61M-$0.37N/A

Surgery Partners presently has a consensus target price of $22.18, indicating a potential upside of 44.88%. Oncology Institute has a consensus target price of $7.25, indicating a potential upside of 36.53%. Given Surgery Partners' stronger consensus rating and higher possible upside, research analysts clearly believe Surgery Partners is more favorable than Oncology Institute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surgery Partners
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Surgery Partners has a net margin of -2.28% compared to Oncology Institute's net margin of -7.42%. Surgery Partners' return on equity of 1.04% beat Oncology Institute's return on equity.

Company Net Margins Return on Equity Return on Assets
Surgery Partners-2.28% 1.04% 0.41%
Oncology Institute -7.42%N/A -24.68%

36.9% of Oncology Institute shares are held by institutional investors. 2.0% of Surgery Partners shares are held by company insiders. Comparatively, 8.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oncology Institute had 2 more articles in the media than Surgery Partners. MarketBeat recorded 3 mentions for Oncology Institute and 1 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.87 beat Oncology Institute's score of 0.75 indicating that Surgery Partners is being referred to more favorably in the media.

Company Overall Sentiment
Surgery Partners Very Positive
Oncology Institute Positive

Surgery Partners has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Summary

Surgery Partners beats Oncology Institute on 10 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Addus HomeCare has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addus HomeCare$1.42B1.22$95.91M$5.4117.24
Oncology Institute$545.76M0.96-$60.61M-$0.37N/A

Addus HomeCare has a net margin of 6.89% compared to Oncology Institute's net margin of -7.42%. Addus HomeCare's return on equity of 9.80% beat Oncology Institute's return on equity.

Company Net Margins Return on Equity Return on Assets
Addus HomeCare6.89% 9.80% 7.34%
Oncology Institute -7.42%N/A -24.68%

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 4.1% of Addus HomeCare shares are held by insiders. Comparatively, 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Addus HomeCare has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, Oncology Institute had 1 more articles in the media than Addus HomeCare. MarketBeat recorded 3 mentions for Oncology Institute and 2 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.79 beat Oncology Institute's score of 0.75 indicating that Addus HomeCare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Addus HomeCare
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncology Institute
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Addus HomeCare currently has a consensus price target of $131.00, indicating a potential upside of 40.44%. Oncology Institute has a consensus price target of $7.25, indicating a potential upside of 36.53%. Given Addus HomeCare's stronger consensus rating and higher probable upside, analysts plainly believe Addus HomeCare is more favorable than Oncology Institute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addus HomeCare
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.70
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Addus HomeCare beats Oncology Institute on 15 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Agilon Health?

Agilon Health (NYSE:AGL) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Agilon Health has a beta of 3, suggesting that its share price is 200% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

36.9% of Oncology Institute shares are owned by institutional investors. 2.3% of Agilon Health shares are owned by company insiders. Comparatively, 8.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Agilon Health has a net margin of -6.09% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat Agilon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Agilon Health-6.09% -146.03% -24.55%
Oncology Institute -7.42%N/A -24.68%

Agilon Health presently has a consensus target price of $58.73, indicating a potential downside of 48.00%. Oncology Institute has a consensus target price of $7.25, indicating a potential upside of 36.53%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than Agilon Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilon Health
2 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.20
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, Oncology Institute had 2 more articles in the media than Agilon Health. MarketBeat recorded 3 mentions for Oncology Institute and 1 mentions for Agilon Health. Oncology Institute's average media sentiment score of 0.75 beat Agilon Health's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agilon Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oncology Institute
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oncology Institute has lower revenue, but higher earnings than Agilon Health. Oncology Institute is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilon Health$5.93B0.32-$391.35M-$21.56N/A
Oncology Institute$545.76M0.96-$60.61M-$0.37N/A

Summary

Oncology Institute beats Agilon Health on 10 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Sonida Senior Living?

Oncology Institute (NASDAQ:TOI) and Sonida Senior Living (NYSE:SNDA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Oncology Institute has a net margin of -7.42% compared to Sonida Senior Living's net margin of -24.15%. Oncology Institute's return on equity of 0.00% beat Sonida Senior Living's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncology Institute-7.42% N/A -24.68%
Sonida Senior Living -24.15%-36.98%-7.08%

Oncology Institute has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Sonida Senior Living has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Oncology Institute had 1 more articles in the media than Sonida Senior Living. MarketBeat recorded 3 mentions for Oncology Institute and 2 mentions for Sonida Senior Living. Sonida Senior Living's average media sentiment score of 0.81 beat Oncology Institute's score of 0.75 indicating that Sonida Senior Living is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncology Institute
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sonida Senior Living
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 87.6% of Sonida Senior Living shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by company insiders. Comparatively, 39.3% of Sonida Senior Living shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oncology Institute has higher revenue and earnings than Sonida Senior Living. Oncology Institute is trading at a lower price-to-earnings ratio than Sonida Senior Living, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncology Institute$545.76M0.96-$60.61M-$0.37N/A
Sonida Senior Living$411.85M4.03-$70.78M-$5.83N/A

Oncology Institute presently has a consensus price target of $7.25, suggesting a potential upside of 36.53%. Sonida Senior Living has a consensus price target of $40.50, suggesting a potential upside of 15.44%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts plainly believe Oncology Institute is more favorable than Sonida Senior Living.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Sonida Senior Living
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Oncology Institute beats Sonida Senior Living on 9 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Viridian Therapeutics?

Oncology Institute (NASDAQ:TOI) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

36.9% of Oncology Institute shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Oncology Institute has a net margin of -7.42% compared to Viridian Therapeutics' net margin of -490.31%. Oncology Institute's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncology Institute-7.42% N/A -24.68%
Viridian Therapeutics -490.31%-80.19%-48.84%

Oncology Institute has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, Viridian Therapeutics had 2 more articles in the media than Oncology Institute. MarketBeat recorded 5 mentions for Viridian Therapeutics and 3 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 0.75 beat Viridian Therapeutics' score of 0.31 indicating that Oncology Institute is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncology Institute
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viridian Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncology Institute currently has a consensus target price of $7.25, suggesting a potential upside of 36.53%. Viridian Therapeutics has a consensus target price of $36.14, suggesting a potential upside of 121.06%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Oncology Institute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Viridian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

Oncology Institute has higher revenue and earnings than Viridian Therapeutics. Oncology Institute is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncology Institute$545.76M0.96-$60.61M-$0.37N/A
Viridian Therapeutics$70.85M23.79-$342.60M-$3.32N/A

Summary

Oncology Institute beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Oncology Institute News Delivered to You Automatically

Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TOI vs. The Competition

MetricOncology InstituteMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$524.84M$8.90B$6.52B$12.05B
Dividend YieldN/A1.71%2.67%5.66%
P/E Ratio-14.3524.2324.0024.42
Price / Sales0.9623.90515.84118.72
Price / CashN/A13.7327.4837.92
Price / Book-33.195.5310.606.82
Net Income-$60.61M$177.22M$3.57B$337.56M
7 Day Performance4.73%1.54%0.59%1.16%
1 Month Performance33.42%10.04%1.54%3.16%
1 Year Performance114.98%5.88%25.41%30.60%

Oncology Institute Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TOI
Oncology Institute
3.8171 of 5 stars
$5.31
flat
$7.25
+36.5%
+115.0%$524.84M$545.76MN/A660
SGRY
Surgery Partners
4.0569 of 5 stars
$13.96
+0.8%
$22.18
+58.9%
-32.7%$1.83B$3.31BN/A16,000
ADUS
Addus HomeCare
3.817 of 5 stars
$92.70
+2.2%
$131.22
+41.6%
-17.3%$1.73B$1.42B17.1350,659
AGL
Agilon Health
1.2196 of 5 stars
$101.74
+6.7%
$58.73
-42.3%
+109.6%$1.70B$5.93BN/A1,076
SNDA
Sonida Senior Living
2.6668 of 5 stars
$35.71
+6.6%
$40.50
+13.4%
N/A$1.69B$411.85MN/A5,140

Related Companies and Tools


This page (NASDAQ:TOI) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners